Neurocrine Biosciences' (NBIX) Buy Rating Reiterated at HC Wainwright

HC Wainwright reiterated their buy rating on shares of Neurocrine Biosciences (NASDAQ:NBIX - Free Report) in a report published on Monday,Benzinga reports. The firm currently has a $190.00 price target on the stock.

NBIX has been the subject of a number of other reports. Cantor Fitzgerald reaffirmed an "overweight" rating and set a $155.00 price objective on shares of Neurocrine Biosciences in a research report on Monday, September 16th. Jefferies Financial Group boosted their price target on shares of Neurocrine Biosciences from $177.00 to $189.00 and gave the stock a "buy" rating in a research note on Monday, August 19th. Barclays reduced their price objective on shares of Neurocrine Biosciences from $180.00 to $160.00 and set an "overweight" rating for the company in a research report on Monday, September 9th. BMO Capital Markets reduced their price objective on Neurocrine Biosciences from $128.00 to $114.00 and set a "market perform" rating on the stock in a research report on Thursday, October 17th. Finally, Needham & Company LLC reissued a "hold" rating on shares of Neurocrine Biosciences in a research note on Monday, November 11th. Five analysts have rated the stock with a hold rating, nineteen have given a buy rating and one has issued a strong buy rating to the stock. Based on data from MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus price target of $165.00.

Neurocrine Biosciences Price Performance

Shares of Neurocrine Biosciences stock traded up $6.35 during trading hours on Monday, hitting $133.05. The company had a trading volume of 1,651,300 shares, compared to its average volume of 869,946. The company's 50-day moving average is $121.75 and its two-hundred day moving average is $130.59. The company has a market cap of $13.47 billion, a P/E ratio of 35.79 and a beta of 0.34. Neurocrine Biosciences has a twelve month low of $110.95 and a twelve month high of $157.98.

Insider Activity

In other news, insider Jude Onyia sold 2,331 shares of Neurocrine Biosciences stock in a transaction on Friday, November 29th. The shares were sold at an average price of $126.29, for a total value of $294,381.99. Following the completion of the sale, the insider now owns 15,449 shares in the company, valued at $1,951,054.21. The trade was a 13.11 % decrease in their position. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Corporate insiders own 4.30% of the company's stock.

Institutional Trading of Neurocrine Biosciences

Hedge funds have recently bought and sold shares of the business. Sumitomo Mitsui DS Asset Management Company Ltd lifted its holdings in Neurocrine Biosciences by 0.8% during the 2nd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 11,436 shares of the company's stock worth $1,574,000 after purchasing an additional 90 shares in the last quarter. Fifth Third Bancorp boosted its position in shares of Neurocrine Biosciences by 14.7% in the second quarter. Fifth Third Bancorp now owns 716 shares of the company's stock valued at $99,000 after acquiring an additional 92 shares during the period. Total Clarity Wealth Management Inc. grew its stake in Neurocrine Biosciences by 4.3% during the second quarter. Total Clarity Wealth Management Inc. now owns 2,433 shares of the company's stock valued at $335,000 after acquiring an additional 100 shares in the last quarter. Commerce Bank increased its holdings in Neurocrine Biosciences by 2.6% during the 3rd quarter. Commerce Bank now owns 4,199 shares of the company's stock worth $484,000 after acquiring an additional 108 shares during the period. Finally, Caprock Group LLC lifted its stake in Neurocrine Biosciences by 7.0% in the 2nd quarter. Caprock Group LLC now owns 1,669 shares of the company's stock worth $230,000 after purchasing an additional 109 shares in the last quarter. 92.59% of the stock is currently owned by institutional investors.

About Neurocrine Biosciences

Neurocrine Biosciences, Inc discovers, develops, and markets pharmaceuticals for neurological, neuroendocrine, and neuropsychiatric disorders in the United States and internationally. The company's products include INGREZZA for tardive dyskinesia and chorea associated with Huntington's disease; ALKINDI for adrenal insufficiency; Efmody capsules for classic congenital adrenal hyperplasia; Orilissa tablets for endometriosis; and Oriahnn capsules to treat uterine fibroids.